Validity and Legacy of Prostate-Specific Antigen (PSA) and PSA-Based Parameters and Isoforms in the New Millennium

European Urology

Volumn 57, Issue 6, 2010, Pages 928-929

  Djavan, Bob ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; ISOPROTEIN; PROSTATE SPECIFIC ANTIGEN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EDITORIAL; EUROPE; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY; VALIDITY;

EARLY DETECTION OF CANCER; HEALTH STATUS INDICATORS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77951622105     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.03.002     Document Type: Editorial

References (13)

1. Djavan B., Remzi M., Zlotta A.R., et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 60 (2002) 4-9
2. Benson M.C., Whang I.S., Olsson C.A., McMahon D.J., and Cooner W.H. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147 (1992) 817-821
3. Carter H.B., and Pearson J.D. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 24 (1997) 333-338
4. Bangma C.H., Kranse R., Blijenberg B.G., and Schröder F.H. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 157 (1997) 544-547
5. Lilja H. Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer. Eur Urol 39 Suppl 4 (2001) 47-48
6. Djavan B., Fong Y.K., Ravery V., et al. Are repeat biopsies required in men with PSA levels ≤4 ng/ml? A multiinstitutional prospective European study. Eur Urol 47 (2005) 38-44 discussion 44
7. Carter H.B., Kettermann A., Ferrucci L., et al. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 70 (2007) 685-690
8. Blijenberg B.G., Yurdakul G., Van Zelst B.D., Bangma C.H., Wildhagen M.F., and Schröder F.H. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 88 (2001) 545-550
9. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
10. Eckersberger E., Finkelstein J., Sadri H., et al. Screening for prostate cancer: a review of the ERSPC and PLCO trials. Rev Urol 11 (2009) 127-133
11. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (2009) 1310-1319
12. Jansen F.H., van Schaik R.H.N., Kurstjens J., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57 (2010) 921-927
13. Herwig R., Mitteregger D., Djavan B., et al. Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA. Eur J Clin Invest 38 (2008) 430-437